Metastatic Solid Tumors Clinical Trial
Official title:
Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.
Study rationale/purpose Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor44 of VEGFR-1, -2, -3, PDGFR-α and -β and c-kit approved for metastatic renal cell carcinoma based on phase III data showing a significant prolongation of progression-free survival (PFS) (5 mos in pretreated patients and 8.3 mos in treatment-naïve patients). In addition recent data was presented this year, but is not yet published, with treatment-refractory sarcoma patients that showed a PFS was significantly prolonged from a median of 20 vs. 7 weeks. As can occur with all antiangiogenic agents, resistance to pazopanib may develop. Epigenetic modification with HDAC inhibitors may overcome drug resistance by causing an increase in accessibility of DNA to chemotherapeutic agents and may therefore significantly potentiate their cytotoxicity. Combination trials with chemotherapy agents are ongoing (ClinicalTrials.gov) To our knowledge, a combination trial of HDACi with anti-angiogenesis agents has not yet been performed and represents an unmet medical need. PCI-24781 is a pan HDAC inhibitor. In cell lines tested, up-regulation and down-regulation of genes known to result in changes with signal transduction, oxidation, metabolic changes, apoptosis, proliferation, differentiation and angiogenesis were seen. In addition, ongoing single agent and combination trials have shown the drug to be effective and well-tolerated. Hypothesis: Combining an antiangiogenic agent, such as pazopanib, with an epigenetic modifier, such as histone deacetylase inhibitor (HDACi) PCI-24781, can increase the efficacy of pazopanib as well as overcome development of resistance to pazopanib. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03993873 -
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05494918 -
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
|
Phase 1 | |
| Completed |
NCT02281409 -
Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT01928459 -
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
|
Phase 1 | |
| Completed |
NCT01449370 -
Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT06031441 -
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03059823 -
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03573544 -
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03893955 -
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT00878423 -
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT00149019 -
Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.
|
Phase 2 | |
| Recruiting |
NCT03093116 -
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
|
Phase 1/Phase 2 | |
| Terminated |
NCT03854227 -
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04094610 -
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
|
Phase 1/Phase 2 | |
| Terminated |
NCT02228811 -
A Study of DCC-2701 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05853367 -
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
|
Phase 1 | |
| Completed |
NCT02097810 -
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.
|
Phase 1 | |
| Recruiting |
NCT05836324 -
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03910530 -
A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT00148993 -
Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
|
Phase 1/Phase 2 |